E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
volunteers at high risk for influenza-related complications (protection against influenza) |
|
E.1.1.1 | Medical condition in easily understood language |
volunteers at high risk for influenza-related complications (protection against flu (influenza)) |
|
E.1.1.2 | Therapeutic area | Body processes [G] - Immune system processes [G12] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10016794 |
E.1.2 | Term | Flu vaccination |
E.1.2 | System Organ Class | 100000004865 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the safety and tolerability of 1 or 2 intramuscular doses (administered 4 weeks apart) of either the cell culture-derived influenza vaccine TIVc or the egg-derived influenza vaccine TIV in children and adolescents 3 to <18 years of age at risk for influenza-related complications. |
|
E.2.2 | Secondary objectives of the trial |
This study has no secondary objectives. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Males and females 3 through 17 years of age at the time of enrollment who are at high risk for influenza-related complications including subjects with confirmed documented medical history of any of the following criteria, as per the WHO recommendations (Weekly Epidemiological Record. 2005;33(80):279-87).
2. Individuals with parents/legal guardians who have given written consent after the nature of the study has been explained according to local regulatory requirements (and where applicable according to local regulations, informed assent for subjects above the specified age).
3. Subjects who, or subjects whose parent/legal guardian, are able to comply with all study procedures and requirements
|
|
E.4 | Principal exclusion criteria |
1. Individuals whose parent(s)/legal guardian(s) are not able to comprehend and to follow all required study procedures for the whole period of the study.
2. Individuals with a history of Guillain-Barré syndrome.
3. Individuals with any fatal prognosis of an underlying medical condition (<12 month life expectancy).
4. Individuals hospitalized at the time of enrolment.
5. Individuals with a history of any anaphylaxis, serious vaccine reactions, or hypersensitivity to any of the vaccine components.
6. Children of research staff involved with the clinical study at this institution or who are otherwise related to research staff or have household members who are research staff associated with the investigator.
7. Individuals with acute disease and/or fever (ie, body temperature measurement ≥38°C [≥100.4°F]) within 3 days prior to vaccination.
8. Individuals who have received vaccines within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to enrolment into this study.
9. Individuals who received another investigational agent within 30 days prior to enrollment or before completion of the safety follow-up period or who are unwilling to refuse to participate in another clinical study through the duration of this study.
10. Individuals who have been immunized with any influenza vaccine (licensed or investigational) within 6 months prior to enrolment or with planned influenza vaccination (other than study vaccine) during the study.
11. Individuals who have been given an antipyretic in the past 24 hours prior to vaccination.
12. Individuals with any other condition which, in the opinion of the investigator, prevents the subject’s participation in the study.
13. Individuals whose parent(s)/legal guardian(s) are unwilling to be contacted by the phone for the safety phone calls or active influenza surveillance.
14. Individuals who are pregnant or breastfeeding.
15. If 9-17 years of age and female, “of childbearing potential”, sexually active, and has not used any of the “acceptable contraceptive methods” for at least 2 months prior to study entry and refuses to use an acceptable contraceptive method through the end of the study.
16. Female subjects of childbearing potential with a positive or indeterminate pregnancy test.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint for this study is safety: proportion of subjects reporting solicited AEs (including local and systemic and other solicited AEs); proportion of subjects reporting unsolicited AEs; proportion of subjects reporting SAEs, new onset of chronic diseases, medically attended AEs, and AEs leading to vaccine/study withdrawal |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
- Solicited adverse events: day of vaccination and the following 6 days (day 1 to day 7 and day 29 to day 35–the latter only for not previously vaccinated subjects);
- Unsolicited adverse events: AEs occurring for approximately 3 to 4 weeks after each vaccination (ie, from day 1 to day 28; and from day 29 to day 49–the latter only for not previously vaccinated subjects);
- SAEs, new onset of chronic diseases, medically attended AEs, and AEs leading to vaccine/study withdrawal: up to day 213 for “not previously vaccinated” subjects 3 to <9 years or up to day 183 for all other subjects. |
|
E.5.2 | Secondary end point(s) |
There are no secondary endpoints in this study |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
There are no secondary endpoints in this study |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 6 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 9 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 7 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial months | 7 |